
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Quinine bark from Cinchona species contains up to 82.93% quinoline alkaloids including quinine, quinidine, cinchonine, and cinchonidine. These alkaloids concentrate in malaria parasite food vacuoles to disrupt heme detoxification and hemoglobin digestion, causing parasite death.

Reported Benefits (Provisional)
Origin & History

Quinine Bark is derived from the Cinchona tree, native to the tropical Andean forests of western South America, particularly Peru, Ecuador, and Colombia. Thriving in montane forests, this bark is historically significant for its potent medicinal alkaloids.
Research Narrative (Provisional)
Quinine bark is extensively documented in scientific literature for its potent antimalarial, antipyretic, and analgesic properties. Numerous clinical studies and historical medical records confirm its efficacy in treating malaria and reducing fever, establishing its significant role in global medicine.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Alkaloids: Quinine, Quinidine, Cinchonine, Cinchonidine (contributing to antimalarial, antipyretic, and analgesic effects). - Flavonoids and Tannins: Present in the bark, offering additional antioxidant and astringent properties.
Reported Mechanism (Provisional)
The primary quinoline alkaloids (quinine, quinidine, cinchonine, and cinchonidine) act as weak bases that concentrate in Plasmodium parasite food vacuoles, where they antagonize Fe(II)-protoporphyrin IX detoxification and block hemoglobin digestion. For anticancer activity, quinine docks to TRAF6 protein to inhibit Ubc13 interaction and induce autophagy and apoptosis in cancer cells. Anti-inflammatory effects occur through NF-κB pathway inhibition by quinolinone derivatives.
Clinical Narrative (Provisional)
Current evidence comes primarily from in vitro studies rather than human clinical trials. Laboratory research shows quinine combined with doxorubicin reduced HeLa cell viability to 11.7 ± 3% and HepG2 cells to 52-63%, with quinine alone demonstrating cytotoxicity at IC50 1.22 ppm. While quinine's antimalarial efficacy is well-established historically, quantified human trial data for other therapeutic applications remains limited. The evidence strength is moderate for antimalarial use but preliminary for anticancer and anti-inflammatory applications.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







